IPGP 10-Q filed 2026-11-03 | Key takeaways
IPGP filed its 10-Q; the most relevant disclosure change is expanded Assets and liabilities held for sale: Belarusian operations classified as held for sale as of June 30, 2026; $17.8M total impairment charges recorded ($17.6M Q2 + $0.2M Q3); government of Belarus approved sale October 14, 2026; expects Q4 2026 close. Customer concentration: One customer (unnamed) represented 12% of accounts_receivable; Five largest customers represented 20% of net_sales.
Key takeaways
Sales: Q3 net sales increased 14.6% to $287.5M, with Industrial Solutions up 11.6% and Advanced Solutions up 32.8%
Belarus divestiture: Operations classified as held for sale due to EU sanctions; $17.8M total impairment charges recorded; government approval received October 14, 2026
Lumibird Medical acquisition: Definitive agreement signed September 8, 2026 for €300M base price plus up to €50M earn-out; expected Q4 2026 close
Trumpf settlement: $13.3M patent litigation payment made in Q2 2026; licensing agreement executed
Tariff refunds: $5.8M recognized in Q3 2026; $10.9M year-to-date as IEEPA tariff refunds deemed probable
Customer concentration: One customer accounted for 12% of accounts receivable at September 30, 2026
Board-approved property sale: Sale of certain properties approved October 30, 2026; estimated ~$25M impairment charge expected in Q4 2026
Key metrics
Customer concentration
Disclosure changes
- Assets and liabilities held for sale
Belarusian operations classified as held for sale as of June 30, 2026; $17.8M total impairment charges recorded ($17.6M Q2 + $0.2M Q3); government of Belarus approved sale October 14, 2026; expects Q4 2026 close
Divestiture addresses EU sanctions restricting component supply from Belarus factory; significant impairment charges recorded - Pending business combination
Share purchase agreement signed September 8, 2026 to acquire Lumibird Medical for €300M cash plus up to €50M contingent earn-out; foreign exchange forward contracts entered to hedge purchase price (€150M notional at 1.17 EUR/USD); expected Q4 2026 close
Material pending acquisition in medical laser space; significant cash outflow of ~$340M+ expected in Q4 2026 - Settlement of litigation matters
$13.3M settlement payment (net of FX) made to Trumpf in Q2 2026 for patent litigation regarding AMB lasers; worldwide license obtained from Trumpf for two patents
Resolved ongoing UPC patent litigation; ongoing royalty obligations reflected in cost of sales - Subsequent events - property sale
Board approved sale of certain properties October 30, 2026; estimated pre-tax impairment charge of ~$25M expected in Q4 2026 to adjust carrying value to fair value less costs to sell; sales expected to close in 2027
Upcoming impairment charge will impact Q4 2026 earnings; real estate footprint optimization initiative - Derivatives
Foreign exchange forward contracts entered August 2026: €150M notional at 1.17 EUR/USD strike; matures October 2026; $5.3M loss recorded in Q3 2026; not designated as hedging instruments
Hedging arrangement for Lumibird acquisition purchase price; mark-to-market losses recognized in earnings - IEEPA tariff refunds
$5.8M tariff refunds recognized in Q3 2026; $10.9M year-to-date; net benefit to gross margin ~170 bps Q3 and ~120 bps YTD; partially offset by $0.8M charges for aluminum import tariff adjustments
Material benefit to margins from IEEPA tariff refund recoveries following Supreme Court ruling
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow IPGP in real time
Get material earnings, filing, IR, and earnings-call alerts by email.